Conference Coverage
Conference Coverage
CMML: GM-CSF inhibitor lenzilumab shows early promise
The PREACH-M trial has yielded encouraging preliminary results in treating CMML, a rare, “insidious” leukemia that can transform into AML.
Conference Coverage
PV: Novel rusfertide shows ‘impressive’ efficacy
The novel synthetic form of liver hormone hepcidin represents a “paradigm shift” in polycythemia vera treatment, allowing patients to avoid the...
Conference Coverage
CLL: Venetoclax-obinutuzumab combo effective long term
Progression-free survival benefit of 1 year with venetoclax-obinutuzumab is sustained long term in chronic lymphocytic leukemia, trial analysis...
Conference Coverage
‘Professional grief’ is a daily reality for oncologists
“We could make the work easier to do so that you have more time with patients and less time with administrative work and have more time to process...
Latest News
Experts share their sun protection tips for children
Most sunscreens are not approved for use in children under the age of 6 months because testing has not been done in this age group, Dr. Adelaide A...
Conference Coverage
Cancer drug shortages spur worry, rationing, and tough choices
Limited supplies of crucial medications are disrupting patient care, oncologists say.
Conference Coverage
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology
A pair of new studies show that drugs can reduce cancer risk when cells are elusive.
Latest News
‘New standard of care’ for capecitabine hand-foot syndrome
“For me as a GI oncologist, topical diclofenac for prevention of HFS for patients on capecitabine is practice changing,” ...
Conference Coverage
It’s okay to say ‘no’: Setting boundaries in oncology
Having set boundaries “provides more emotional and cognitive flexibility, and less uncertainty, in the relationships that we have with our...
Conference Coverage
Less therapy may suit older patients with breast cancer
“Do we absolutely have to do a mastectomy for a patient who has a second episode of cancer in the same breast? The answer is no.”
Conference Coverage
New study backs up capecitabine dosing practice in metastatic BC
Study finds similar progression-free and overall survival in 7-day-on/7-day-off schedule, with fewer side effects than 14 days on, 7 days off.